Drug Trial Radar · NCT04121676
Anti-CD137 and Anti-CTLA-4 Monoclonal Antibody in Patients With Advanced Cancer
Last checked: Nov 19, 2026Latest source record: Jan 13, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
91
Actual
Start
Sep 26, 2019
Primary completion
Feb 22, 2024
Study completion Nov 30, 2024
Sponsor
- Lead sponsor
- Agenus Inc.Industry
- Sponsor type
- Industry
- First posted
- Oct 10, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is an open-label, Phase 1, multicenter study to evaluate the safety, tolerability, PK, and PD profiles of AGEN2373 as a monotherapy and in combination with botensilimab (also known as AGEN1181), and to assess the maximum tolerated dose (MTD) in subjects with advanced solid tumors.
Conditions
- Advanced Cancer
Interventions
AGEN2373Drug
An Anti-CD137 Monoclonal Antibody
BotensilimabDrug
Anti-CTLA-4 Monoclonal Antibody
Primary outcomes
What the sponsor says the trial is designed to measure.
- Occurrence of Dose Limiting Toxicity (DLT)Time frame: First 28 days of treatment Q2W and Q4W and First 21 days Q3W
- Frequency of treatment-emergent adverse events (TEAEs)Time frame: Screening to 90 days from last dose
- Severity of treatment-emergent adverse events (TEAEs)Time frame: Screening to 90 days from last dose
- Duration of treatment-emergent adverse events (TEAEs)Time frame: Screening to 90 days from last dose
Locations
12 sites in 1 country. Site status is shown where the registry gives one.
University of Southern California Norris Comprehensive Cancer Center/ Hoag
Los Angeles, California
University of Colorado Anschutz Medical Campus
Aurora, Colorado
University of Miami
Coral Gables, Florida
Moffitt Cancer Center
Tampa, Florida
Atlantic Health System
Morristown, New Jersey
Roswell Park Comprehensive Cancer Care
Buffalo, New York
Columbia University
New York, New York
Providence Cancer Institute
Portland, Oregon
UPMC
Pittsburgh, Pennsylvania
Mary Crowley Cancer Research Center
Dallas, Texas
NEXT Oncology
San Antonio, Texas
University of Washington
Seattle, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.